Last checked at 16 Oct 2017 16:40
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||
a) | Name | Ms E Walmsley | ||||||||||
b) | Position/status | Chief Executive Officer | ||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. | ||||||||||
c) | Price(s) and volume(s) |
| ||||||||||
d) | Aggregated information
Aggregated volume Price |
9,616.827 £15.2750
| ||||||||||
e) | Date of the transaction | 2017-10-12 | ||||||||||
f) | Place of the transaction
| n/a | ||||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||
a) | Name | Mr R G Connor | ||||||||
b) | Position/status | President, Global Manufacturing & Supply | ||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | GlaxoSmithKline plc | ||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information
Aggregated volume Price |
4,378.382 £15.2750
| ||||||||
e) | Date of the transaction | 2017-10-12 | ||||||||
f) | Place of the transaction
| n/a | ||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||
a) | Name | Mr L Debruyne | ||||||||
b) | Position/status | President, Global Vaccines | ||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | GlaxoSmithKline plc | ||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information
Aggregated volume Price |
1,869.387 £15.2750
| ||||||||
e) | Date of the transaction | 2017-10-12 | ||||||||
f) | Place of the transaction
| n/a | ||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||
a) | Name | Mr S Dingemans | ||||||||
b) | Position/status | Chief Financial Officer | ||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | GlaxoSmithKline plc | ||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information
Aggregated volume Price |
8,086.638 £15.2750
| ||||||||
e) | Date of the transaction | 2017-10-12 | ||||||||
f) | Place of the transaction
| n/a | ||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||
a) | Name | Mr N Hirons | ||||||||
b) | Position/status | SVP, Global Ethics & Compliance | ||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | GlaxoSmithKline plc | ||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information
Aggregated volume Price |
1,829.052 £15.2750
| ||||||||
e) | Date of the transaction | 2017-10-12 | ||||||||
f) | Place of the transaction
| n/a | ||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||
a) | Name | Mr B McNamara | ||||||||||
b) | Position/status | CEO, GSK Consumer Healthcare | ||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053
| ||||||||||
b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Performance Share Plan. | ||||||||||
c) | Price(s) and volume(s) |
| ||||||||||
d) | Aggregated information
Aggregated volume Price |
2,176.780 $41.02
| ||||||||||
e) | Date of the transaction | 2017-10-12 | ||||||||||
f) | Place of the transaction
| n/a | ||||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||
a) | Name | Mr D S Redfern | ||||||||
b) | Position/status | Chief Strategy Officer | ||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | GlaxoSmithKline plc | ||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information
Aggregated volume Price |
3,248.246 £15.2750
| ||||||||
e) | Date of the transaction | 2017-10-12 | ||||||||
f) | Place of the transaction
| n/a | ||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||
a) | Name | Ms C Thomas | ||||||||
b) | Position/status | SVP, HR | ||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | GlaxoSmithKline plc | ||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information
Aggregated volume Price |
3,992.150 £15.2750
| ||||||||
e) | Date of the transaction | 2017-10-12 | ||||||||
f) | Place of the transaction
| n/a | ||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||||||||
a) | Name | Mr P C Thomson | |||||||||
b) | Position/status | President, Global Affairs | |||||||||
c) | Initial notification/ amendment | Initial notification | |||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||
a) | Name | GlaxoSmithKline plc | |||||||||
b) | LEI | 5493000HZTVUYLO1D793 | |||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| |||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. | |||||||||
c) | Price(s) and volume(s) |
| |||||||||
d) | Aggregated information
Aggregated volume Price |
2,363.099 £15.2750
| |||||||||
e) | Date of the transaction | 2017-10-12 | |||||||||
f) | Place of the transaction
| n/a | |||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||
a) | Name | Mr D E Troy | ||||||||
b) | Position/status | SVP & General Counsel | ||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | GlaxoSmithKline plc | ||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053
| ||||||||
b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Performance Share Plan. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information
Aggregated volume Price |
3,601.866 $41.02
| ||||||||
e) | Date of the transaction | 2017-10-12 | ||||||||
f) | Place of the transaction
| n/a | ||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||
a) | Name | Dr P J T Vallance | ||||||||
b) | Position/status | President, R&D | ||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | GlaxoSmithKline plc | ||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information
Aggregated volume Price |
9,294.681 £15.2750
| ||||||||
e) | Date of the transaction | 2017-10-12 | ||||||||
f) | Place of the transaction
| n/a | ||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||
a) | Name | Mrs V A Whyte | ||||||||
b) | Position/status | Company Secretary | ||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | GlaxoSmithKline plc | ||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information
Aggregated volume Price |
480.617 £15.2750
| ||||||||
e) | Date of the transaction | 2017-10-12 | ||||||||
f) | Place of the transaction
| n/a | ||||||||